BCX4430

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
BCX4430
BCX4430.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C11H15N5O3
Molar mass 265.268
3D model (JSmol)

BCX4430 (Immucillin-A) is an antiviral drug, an adenosine analog[1] (a type of nucleoside analog).[2] It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection,[1] and development for use in humans is being fast-tracked due to concerns about the lack of treatment options for the 2013-2016 Ebola virus epidemic in West Africa.[3] BCX4430 also showed efficacy against Zika virus in a mouse model, though there are no plans for human trials at this stage.[4]

See also[edit]

References[edit]

  1. ^ a b Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. (April 2014). "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430". Nature. 508 (7496): 402–5. Bibcode:2014Natur.508..402W. doi:10.1038/nature13027. PMID 24590073. 
  2. ^ Kamat SS, Burgos ES, Raushel FM (October 2013). "Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate". Biochemistry. 52 (42): 7366–8. doi:10.1021/bi4013287. PMC 3838859Freely accessible. PMID 24111876. 
  3. ^ Rodgers P (8 April 2014). "BioWar Lab Helping To Develop Treatment For Ebola". Forbes Magazine. 
  4. ^ Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, et al. (January 2017). "Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model". Antiviral Research. 137: 14–22. doi:10.1016/j.antiviral.2016.11.003. PMC 5215849Freely accessible. PMID 27838352.